Kardigan expects six-month Danicamptiv data in Q2 of next year, covering echocardiographic parameters and a directional change in peak VO2. Those correlations could confirm sizing for the 250-patient registrational study. Atasaguat registrational trial details are due in the first half of next year.
KARD · Kardigan, Inc.
The latest filing states the doubt was alleviated.
“the Company previously concluded that recurring losses, negative cash flows from operations, and limited liquidity raised substantial doubt about its ability to continue as a going concern. In June 2026, the Company completed its IPO and received net proceeds of approximately $422.5 million. Upon closing of the IPO and receipt of the associated net proceeds, the Company alleviated the substantial doubt that previously existed.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
The closing range uses available history since Jun 18, 2026; less than a full year is stored.
Latest documents
Cardigan said six-month data for Danicamptiv in genetic cardiomyopathy comes in the second quarter, with peak VO2 correlations. Week 48 data for Atasaguat in Catalyst AV will confirm AVA and peak VO2, with registrational trial details in the first half of next year. About 80% of mild and moderate aortic stenosis patients show cardiac damage.
Kardigan advanced three late-stage programs—Danicamtiv, Ataciguat and Tonlamarsen—and expects clinical data in 2027. It reported $591.4 million in cash, cash equivalents and investments and a $230.9 million nine-month net loss.
Kardigan completed enrollment in Cohort 2 of the Phase 2b danicamtiv KINSHIP-DCM trial, with topline data expected in 2Q 2027; it also completed ataciguat KATALYST-AV Phase 2b enrollment, with data expected in 2H 2027. Cash was $591.4 million.
Kardigan completed enrollment in its Phase 2b KATALYST-AV trial of ataciguat for aortic stenosis, moving primary endpoint assessment to Week 48 and topline data to 2H 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash Position | $591.4M | as of September 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KARD
this stock
Kardigan, Inc.
|
$1.15B | — | — | — | 6.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 11
Kardigan expects six-month Danicamptiv data in Q2 of next year, covering echocardiographic parameters and a directional change in peak VO2. Those correlations could confirm sizing for the 250-patient registrational study. Atasaguat registrational trial details are due in the first half of next year.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KARD | -21.4% | -4.1% | — | -12.8% | — |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -17.5% | +1.4% | — | -9.4% | — |